[Recent Advances in Hepatitis B Virus Antivirals]

Area of Science:

• Hepatology and Virology
• Immunology
• Pharmacology

Background:

• Chronic hepatitis B virus (HBV) infection is difficult to eradicate with current therapies like entecavir and tenofovir disoproxil fumarate.
• Treatment limitations stem from the persistence of covalently closed circular DNA (cccDNA) in hepatocytes and inadequate host immune responses.
• Existing treatments include nucleos(t)ide analogues (NAs), non-NAs, and immunomodulatory agents, each with distinct benefits and drawbacks.

Purpose of the Study:

• To review recent advancements in HBV drug research and development.
• To highlight novel therapeutic strategies targeting both viral replication and host immune responses.
• To address the urgent need for new drugs capable of achieving complete HBV eradication.

Main Methods:

• Comprehensive literature review of recent studies on HBV drug development.
• Analysis of breakthroughs in understanding cccDNA persistence.
• Evaluation of emerging host immune-based treatment strategies.

Main Results:

• Current first-line HBV therapies are insufficient for complete viral eradication.
• Significant progress has been made in understanding the role of cccDNA.
• Novel therapeutic targets and immune-modulating approaches are under investigation.

Conclusions:

• Developing novel anti-HBV drugs is crucial for achieving a functional cure.
• Future strategies should integrate therapies targeting viral persistence and enhancing immune control.
• Continued research into cccDNA and host immunity is essential for advancing HBV treatment.